SABCS: Merck's Keytruda notches win in triple-negative breast cancer as Roche's Tecentriq falls short

Merck & Co.'s Keytruda and Roche's Tecentriq are battling for immuno-oncology supremacy in an ever-growing range of indications. But in hard-to-treat triple-negative breast cancer (TNBC), Keytruda's latest data came out on top.